enGene (ENGN) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

ENGN · Stock Price

USD 1.72-1.24 (-41.89%)

Market Cap: $110.5M

Historical price data

Market Cap: $110.5MPipeline: 1 drugPatents: 10HQ: Montreal, Canada

Sector Ranking#61 in Cell & Gene Therapy #90 in Drug Delivery & Formulation

Overview

enGene's mission is to mainstream genetic medicine by developing non-viral therapeutics delivered directly to mucosal tissues, starting with urological cancers. Its key achievement is advancing detalimogene into the pivotal LEGEND trial for NMIBC, supported by FDA RMAT and Fast Track designations. The company's strategy is to validate its proprietary DDX platform with this lead asset and subsequently expand its pipeline into other serious diseases affecting mucosal organs. enGene is publicly traded on NASDAQ, providing capital to execute its focused clinical and platform development plans.

OncologyUrology

Technology Platform

Proprietary DDX® (Dually Derivatized Oligochitosan) platform, a non-viral nanoparticle system engineered for efficient localized gene delivery to mucosal tissues, designed to overcome limitations of viral vectors.

Pipeline

1

1 drug in pipeline

Drug	Indication	Stage	Watch
EG-70 (phase 1) + EG-70 (phase 2)	Superficial Bladder Cancer	Phase 1/2

Funding History

4

Total raised:$370M

IPO$90MUndisclosedNov 9, 2023

Series C$200MFrazier Life SciencesOct 15, 2022

Series B$65MForbionDec 15, 2020

Series A$15MFonds de solidarité FTQJun 15, 2018

Opportunities

A successful lead program in NMIBC validates the DDX platform, unlocking a pipeline opportunity across multiple mucosal tissue diseases (e.g., IBD, lung diseases) representing tens of billions in market potential.

The non-viral approach offers key commercial advantages in manufacturing, re-dosing, and safety.

Risk Factors

The company faces binary clinical risk with its single lead asset; failure in the pivotal LEGEND trial would severely impact valuation.

Additional risks include regulatory uncertainty for a novel modality, future capital needs, and competition in the NMIBC market from approved and emerging therapies.

Competitive Landscape

In NMIBC, detalimogene competes against approved viral gene therapy (Adstiladrin) and checkpoint inhibitors, differentiating via its non-viral, dual-cytokine mechanism. Broader platform competitors include other non-viral delivery technologies, but enGene's specific focus on mucosal tissue delivery is a key differentiator.